Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2001;24(3):273-87.
doi: 10.1385/IR:24:3:273.

Sepsis-induced immunosuppression: from bad to worse

Affiliations
Review

Sepsis-induced immunosuppression: from bad to worse

R C Reddy et al. Immunol Res. 2001.

Abstract

The sepsis syndrome is characterized by the acute release of a variety of inflammatory mediators, which often result in detrimental effects to the host. The release of these mediators is regulated and counterbalanced by the coordinated expression of antiinflammatory molecules. It is the balance between the expression of pro- and antiinflammatory mediators that often determines the magnitude of early tissue injury and subsequent risk of infectious complications. As our understanding of the pathophysiology of sepsis continues to evolve, we have gained a greater appreciation for the effects that sepsis and similar states of overwhelming stress have on host antimicrobial immunity. A number of functional defects in leukocytes isolated from sepsis patients have been characterized. These defects include diminished expression of important cell surface antigens, dysregulated cytokine production, alterations in antigen-presenting ability, and accelerated apoptosis. Impaired leukocyte function has important clinical ramifications, as high mortality rates have been observed in patients displaying evidence of sepsis-induced immune deactivation. In this article, we review the current literature supporting evidence of dysregulation of host immunity occurring during sepsis syndrome, characterize the underlying pathophysiology, and describe novel therapeutic interventions directed at augmenting host immunity during sepsis.

PubMed Disclaimer

References

    1. Eur J Immunol. 1994 May;24(5):1167-71 - PubMed
    1. Infect Immun. 1998 Jun;66(6):2822-6 - PubMed
    1. Infect Immun. 1988 Oct;56(10):2563-9 - PubMed
    1. J Immunol. 1994 May 15;152(10):5014-21 - PubMed
    1. J Immunol. 1992 Nov 1;149(9):2977-83 - PubMed

Publication types